Search

everythinglearnresearchcommunity

for

Search:↓

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.

The conditions alopecia areata, primary sclerosing cholangitis, and ulcerative colitis may be linked by shared autoimmune and cell death mechanisms.

EPDS and MS might share an immune-related cause.

Warming hands improves blood flow in people with systemic sclerosis.

Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Intralesional cidofovir might be a viable alternative treatment for certain conditions.

Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.

Autoimmune diseases like lupus, dermatomyositis, and scleroderma can cause hair loss and other hair problems, and treatments for these diseases might also affect hair.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Skin problems like psoriasis and systemic sclerosis can increase the risk of heart disease, so doctors should watch for heart risks in patients with these conditions.

Small molecule DMF improves psoriasis and multiple sclerosis, adult skin cells can be made to grow new hair, certain skin cells initiate hair growth, IL-17C controls gut health and can cause skin inflammation, and skin cells produce IL-17 that can lead to psoriasis.

Hyperbaric oxygen therapy shows promise for multiple sclerosis, but skepticism and funding issues limit tech use in clinics, and outdated single-drug cancer treatments may cause unnecessary side effects.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Severe allergic reactions to hair dye can trigger hair loss and may be linked to multiple sclerosis.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

Coats' Plus is a genetic disorder with eye abnormalities, brain calcification, poor growth, bone and skin issues, and movement disorders.

Targeting the skin's endocannabinoid system could help treat skin disorders.

Excimer light effectively treats various skin diseases, including psoriasis, vitiligo, and mycosis fungoides.

Skin conditions in multiple myeloma patients vary with the timing of bone marrow transplants.